Logos Global Management LP Cuts Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Logos Global Management LP decreased its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 62.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 595,000 shares of the company’s stock after selling 979,220 shares during the period. Enliven Therapeutics comprises approximately 1.1% of Logos Global Management LP’s holdings, making the stock its 25th biggest holding. Logos Global Management LP’s holdings in Enliven Therapeutics were worth $13,905,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after buying an additional 305,397 shares during the period. First Turn Management LLC acquired a new position in Enliven Therapeutics during the 2nd quarter worth $9,657,000. Baker BROS. Advisors LP acquired a new position in Enliven Therapeutics during the 1st quarter worth $2,020,000. Bank of New York Mellon Corp grew its holdings in Enliven Therapeutics by 49.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares in the last quarter. Finally, Nicholas Investment Partners LP acquired a new position in Enliven Therapeutics during the 2nd quarter worth $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Up 1.6 %

Shares of NASDAQ:ELVN opened at $23.57 on Tuesday. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $27.67. The company has a market cap of $1.11 billion, a PE ratio of -12.21 and a beta of 1.09. The company’s 50-day moving average price is $23.02 and its 200 day moving average price is $21.31.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on ELVN shares. Robert W. Baird started coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective for the company. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, HC Wainwright began coverage on shares of Enliven Therapeutics in a report on Monday, September 9th. They issued a “buy” rating and a $37.00 price target for the company.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 3,099 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $27.56, for a total transaction of $85,408.44. Following the transaction, the insider now directly owns 1,089,936 shares of the company’s stock, valued at $30,038,636.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Joseph P. Lyssikatos sold 3,099 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $27.56, for a total transaction of $85,408.44. Following the transaction, the insider now directly owns 1,089,936 shares of the company’s stock, valued at $30,038,636.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 991 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $27.53, for a total transaction of $27,282.23. The disclosure for this sale can be found here. Insiders have sold a total of 123,805 shares of company stock valued at $3,068,192 over the last ninety days. Corporate insiders own 29.20% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.